hypereosinophilic syndrome

Showing 1 - 25 of 25

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Hypereosinophilic Syndrome Trial in Worldwide (Benralizumab, Placebo)

Recruiting
  • Hypereosinophilic Syndrome
  • Benralizumab
  • Placebo
  • La Jolla, California
  • +45 more
Feb 2, 2023

Hypereosinophilic Syndrome Trial (Depemokimab, Placebo)

Recruiting
  • Hypereosinophilic Syndrome
  • Atlanta, Georgia
  • +18 more
Feb 1, 2023

Eosinophilic Myeloid Tumor, Hypereosinophilic Syndrome Trial run by the National Institute of Allergy and Infectious Diseases

Recruiting
  • Eosinophilic Myeloid Neoplasm
  • Hypereosinophilic Syndrome
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

Recruiting
  • BCR-JAK2 Fusion Protein Expression
  • +11 more
  • Palo Alto, California
  • +3 more
Oct 5, 2022

Hypereosinophilic Syndrome Trial in Argentina, Spain, United States (Mepolizumab)

Recruiting
  • Hypereosinophilic Syndrome
  • Rochester, Minnesota
  • +8 more
Aug 11, 2022

Familial Hypereosinophilia: Natural History and Markers of

Recruiting
  • Eosinophilia
  • Hypereosinophilic Syndrome
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Apr 7, 2022

    Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder Trial run by the NIAID (prednisone)

    Completed
    • Eosinophilia
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Jan 26, 2022

    Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera Trial in Houston (Imatinib Mesylate (Gleevec))

    Completed
    • Chronic Myelomonocytic Leukemia
    • +4 more
    • Imatinib Mesylate (Gleevec)
    • Houston, Texas
      UT MD Anderson Cancer Center
    Dec 7, 2021

    Eosinophilia, Hypereosinophilic Syndrome Trial in Stanford (Gleevec)

    Terminated
    • Eosinophilia
    • Hypereosinophilic Syndrome
    • Stanford, California
      Stanford University School of Medicine
    May 5, 2021

    Hypereosinophilic Syndrome Trial (Mepolizumab)

    No longer available
    • Hypereosinophilic Syndrome
    • (no location specified)
    Nov 23, 2020

    Hypereosinophilia and Hypereosinophilic Syndromes

    Recruiting
    • Eosinophilia
    • Hypereosinophilic Syndrome
    • Biological sample
    • Lille, France
      Hôpital Roger Salengro, CHU
    Aug 25, 2020

    Hypereosinophilic Syndrome Trial in Worldwide (Mepolizumab)

    Completed
    • Hypereosinophilic Syndrome
    • La Jolla, California
    • +35 more
    Jun 4, 2020

    Hypereosinophilia, Hypereosinophilic Syndrome Trial in Worldwide (mepolizumab)

    Completed
    • Hypereosinophilia
    • Hypereosinophilic Syndrome
    • San Diego, California
    • +28 more
    May 1, 2020

    Hypereosinophilic Syndrome Trial in Worldwide (Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg

    Completed
    • Hypereosinophilic Syndrome
    • Mepolizumab 300 mg
    • +3 more
    • San Diego, California
    • +42 more
    Feb 7, 2020

    Hypereosinophilic Syndrome Trial in Limoges (Scheduled exams and diagnosis)

    Unknown status
    • Hypereosinophilic Syndrome
    • Scheduled exams and diagnosis
    • Limoges, France
      Médecine Interne A
    Jun 4, 2019

    Acute Myeloid Leukemia, MDS, Agnogenic Myeloid Metaplasia Trial in Houston (Dasatinib (BMS-354825))

    Completed
    • Acute Myeloid Leukemia
    • +7 more
    • Dasatinib (BMS-354825)
    • Houston, Texas
      The University of Texas M.D. Anderson Cancer Center
    May 2, 2019

    Hypereosinophilic Syndrome Trial in Lille (biologie sample)

    Completed
    • Hypereosinophilic Syndrome
    • biologie sample
    • Lille, Nord, France
      CHRU, Hôpital Claude Huriez
    Feb 14, 2019

    Hypereosinophilic Syndrome Trial run by the NIAID (Dexpramipexole)

    Unknown status
    • Hypereosinophilic Syndrome
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Dec 6, 2017

    Hypereosinophilic Syndrome Trial in Worldwide (mepolizumab)

    Terminated
    • Hypereosinophilic Syndrome
    • San Diego, California
    • +23 more
    Jun 7, 2017

    Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia Trial in East Melbourne (imatinib mesylate)

    Completed
    • Hypereosinophilic Syndrome
    • +3 more
    • imatinib mesylate
    • East Melbourne, Australia
      Novartis Investigative Site
    Feb 21, 2017

    Hypereosinophilic Syndrome Trial in Leuven (imatinib mesylate)

    Terminated
    • Hypereosinophilic Syndrome
    • imatinib mesylate
    • Leuven, Belgium
      Novartis Investigative Site
    Apr 29, 2012

    Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL), Myeloproliferative Disorders Trial in Italy (STI571)

    Unknown status
    • Hypereosinophilic Syndrome
    • +2 more
    • Bologna, Italy
    • +13 more
    Sep 14, 2009

    Hypereosinophilic Syndrome Trial run by the NIAID (SCH55700)

    Completed
    • Hypereosinophilic Syndrome
    • Bethesda, Maryland
      National Institute of Allergy and Infectious Diseases (NIAID)
    Mar 3, 2008